Startup profile · funding coverage
Anagram Therapeutics funding, valuation and investors
Clinical-stage biotech developing non-porcine oral enzyme therapies to replace 15–40 daily pills for pancreatic insufficiency.
Keep track of Anagram Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Strategic investment
$250M · May 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$250M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Natick, Massachusetts
Investors in latest funding
Lead: Blackstone Life Sciences
Overview
Anagram Therapeutics is a clinical-stage biopharmaceutical company based in Natick, Massachusetts, developing orally delivered recombinant enzyme therapies for malabsorption diseases. Its lead candidate, ANG003, is a broad-spectrum non-porcine enzyme replacement therapy for exocrine pancreatic insufficiency (EPI) — a condition affecting many cystic fibrosis patients who currently take 15–40 daily capsules of pig-derived pancreatic enzyme replacement therapy (PERT). ANG003 entered a Phase 2 trial (NCT07450547) in 2026 comparing safety and efficacy against Creon. In May 2026, Blackstone Life Sciences invested $250M to fund development through approval and launch. Prior support includes $30M+ from the Cystic Fibrosis Foundation.
Why Anagram Therapeutics is interesting
Anagram's lead drug ANG003 targets a mundane but brutal CF burden — up to 40 pig-derived enzyme pills daily — with a once-per-meal recombinant tablet. Blackstone's $250M bet is on pill-burden reduction, not platform hype.
Product & use cases
Pipeline of orally delivered recombinant enzyme replacement therapies for gastrointestinal malabsorption. Lead product ANG003 replaces pig-derived PERT with a stable, broad-spectrum lipase/protease/amylase tablet designed for once-per-meal dosing.
- Exocrine pancreatic insufficiency in cystic fibrosis patients
- EPI due to pancreatic cancer and related disorders
- Future pipeline candidates (ANG011, ANG021, ANG031) for enzyme-deficiency malabsorption
Key facts
- $250M Blackstone Life Sciences investment (May 7, 2026)
- ANG003 in Phase 2 trial NCT07450547 vs Creon for CF-related EPI
- $30M+ prior Cystic Fibrosis Foundation funding for ANG003 development
- Founded 2020; team with 25+ years GI/rare-disease domain expertise
- Potential first non-porcine extract EPI product if approved
Funding history (newest first)
Strategic investment
2026-05 $250M- Blackstone Life Sciences (lead)
Competitive landscape
Edge: Non-porcine recombinant enzymes engineered for immediate GI activity without heavy enteric coating — potentially one tablet per meal versus up to 40 daily pig-derived capsules, addressing global PERT shortages.
EPI treatment is dominated by decades-old pig-pancreas extracts with high pill burden and periodic shortages. Anagram's thesis — recombinant oral enzymes with lower daily capsule count — is clinically testable in Phase 2. Success requires beating Creon on efficacy and tolerability, not just convenience.
-
AbbVie (Creon) incumbent
Market-leading porcine-derived PERT; ANG003's Phase 2 uses Creon as active comparator.
-
Nestlé Health Science (Zenpep) incumbent
Major PERT brand with established CF prescriber relationships and global supply chains.
-
AzurRx BioPharma adjacent
Other biotechs exploring next-gen enzyme and malabsorption therapies; Anagram leads on non-porcine recombinant oral ERT data.
Notable stories
- Endpoints News reported Blackstone's $250M is intended to fund ANG003 'development, approval and launch' — a single-asset life-sciences bet from a firm that typically backs programs to clinical proof or exit.
- Anagram's March 2026 leadership expansion (new CMO, CFO, COO promotion) coincided with Phase 2 trial initiation — signaling operational scale-up ahead of pivotal readouts.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Anagram Therapeutics's financing or category context.
FAQs about Anagram Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.